了解低收入中等收入国家对C型肝炎抗病毒治疗的障碍
Rashmi Venkatesh1, Andrew S Huang2, Kiya Gurmessa3
1College of Osteopathic Medicine, William Carey University, Hattiesburg, MS 39401, USA.
Healthcare (Basel, Switzerland)
|January 10, 2025
概括
由于资金和认识差距,在低收入和中等收入国家治疗C型肝炎病毒 (HCV) 仍然是一个挑战. 解决这些障碍对于到2030年全球消除HCV至关重要.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 公共卫生 公共卫生
- 传染性疾病 传染性疾病
背景情况:
- 自2011年以来,直接作用的抗病毒药物 (DAA) 已经彻底改变了C型肝炎病毒 (HCV) 治疗.
- 尽管DAA取得了进展,但全球仍有超过7000万个人没有接受治疗,而低收入和中等收入国家 (LMICs) 的负担很大.
研究的目的:
- 确定和分析在LMICs中治疗HCV的关键障碍.
- 提出可行的建议,以改善资源有限的环境中的HCV治疗机会.
主要方法:
- 进行了对开放获取信息来源的结构化搜索.
- 进行了非正式的同行评审文献审查,以确定HCV治疗的挑战.
- 确定障碍被编译,分析,并为LMICs主题.
主要成果:
- 主要障碍包括诊断不足和治疗不足,与查和测试的资金和医疗保健基础设施不足有关.
- 医疗保健提供者的认识不足以及与疾病相关的错误信息和污名化进一步阻碍了获得治疗的机会.
- 缺乏基本诊断和治疗的机会仍然是LMICs的一个关键问题.
结论:
- 低低收入国家必须实施教育媒体发行,移动诊所和国际伙伴关系等战略,以克服HCV治疗障碍.
- 实现世界卫生组织2030年消除HCV的目标需要共同努力,减少护理差距,确保对测试和治疗的普遍准入.
- 已在发达国家证明的成功干预措施为LMICs提供了一份路线图,以改善HCV的结果.
更多相关视频
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
13.2K
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.1K
相关概念视频
01:10Retrovirus Life Cycles
45.6K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.6K
01:23Factors Affecting Drug Distribution: Physiological Barriers
167
Drug distribution in the body is intricately regulated by various physiological barriers that control the passage of substances. These include the capillary endothelial barrier, the blood-brain, blood-cerebrospinal fluid, blood-placental, and blood-testis barriers.
The capillary endothelial barrier allows only smaller molecules below 600 Da (Daltons) to pass through. It also restricts drugs like heparin that are bound to blood components, limiting their movement within the bloodstream.
The...
The capillary endothelial barrier allows only smaller molecules below 600 Da (Daltons) to pass through. It also restricts drugs like heparin that are bound to blood components, limiting their movement within the bloodstream.
The...
167
01:14Hepatic Drug Clearance: Role of Transporters
34
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
34
01:29Pulmonary Tuberculosis I
220
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
220